Unusual Variant of Lupus Erythematosus or Lichen Planus

Romero, Robert W.

doi:10.1001/archderm.1977.01640060037002

Cited by 59 publications

(15 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…ANAs are usually negative or present at a low titre and the work-up results for SLE are negative. 7 Therefore, in our case, the high levels of ANAs and the presence of anaemia, as well as arthralgias and skin lesions, suggest a systemization of the disease. Only a combination of systemic corticoids, retinoids and antimalarials was able to achieve nail improvement and this partial resistance to therapy may be explained by the very unusual subungual hyperkeratosis.…”

Section: Discussionsupporting

confidence: 48%

Hyperkeratotic nail discoid lupus erythematosus evolving towards systemic lupus erythematosus: therapeutic difficulties

Richert

André²,

Bourguignon

et al. 2004

Acad Dermatol Venereol

View full text Add to dashboard Cite

Nail changes occur in about 25% of systemic lupus erythematosus (SLE) cases. Onycholysis has been reported as the most frequent abnormality in SLE. Nailbed hyperkeratosis may be observed in both SLE and discoid lupus erythematosus (DLE). Involvement of the nail apparatus in DLE is extremely uncommon and never restricted to it. We report on a patient in whom the clinical features on the proximal nailfold were similar to those observed on the skin of a patient with typical DLE. This has, to the best of our knowledge, not yet been reported. The patient also exhibited a very distinctive prominent subungual hyperkeratosis. Interestingly, the patient developed biological alterations suggesting a systematization of the disease. Only a combination of systemic corticoids, retinoids and antimalarials was able to achieve nail improvement and this partial resistance to therapy may be explained by the very unusual subungual hyperkeratosis.

show abstract

Section: Discussionsupporting

confidence: 48%

Hyperkeratotic nail discoid lupus erythematosus evolving towards systemic lupus erythematosus: therapeutic difficulties

Richert

André²,

Bourguignon

et al. 2004

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…Several reports show antibodies against 180, 130 and 200 kDa epidermal antigens [40,44,45,46,47,48,49,50,51]. Some reports also describe an overlap between LP and lupus erythematosus [52,53,54,55,56,57]. …”

Section: Discussionmentioning

confidence: 99%

Oral, Esophageal and Cutaneous Lichen Ruber Planus Controlled with Alitretinoin: Case Report and Review of the Literature

Kolios¹,

Maggio²,

Gubler

et al. 2013

Dermatology

View full text Add to dashboard Cite

Background: Therapy-resistant lichen planus (LP) can be a challenging condition for dermatologists. There are some case reports about successful treatments with alitretinoin of cutaneous and oral, but not of esophageal LP. Objective: We present the unique case of a patient with cutaneous, oral and esophageal LP which was refractory to classical treatment options (topical clobetasol propionate and pimecrolimus, intramuscular triamcinolone acetonide); because of systemic side effects the patient did not tolerate systemic acitretin dosed up to 25 mg daily. Methods: Oral alitretinoin was used at a dose of 30 mg daily. Results: Both oral and skin changes as well as dysphagia completely resolved within 4 weeks without any severe side effects and the drug was used for 6 months. No papules, intraoral striae or dysphagia recurred during the 6 months of treatment. After 4 months the patient relapsed with mucosal patches so that a second cycle was initiated for 6 months where oral LP lesions resolved after 4 weeks also (with sporadic mild headache). Conclusion: Further studies are needed to better understand the impact of alitretinoin in LP. Our observation suggests alitretinoin as a new, well-tolerated treatment option for esophageal LP after failed response to conventional treatments.

show abstract

“…Many clinically distinct inflammatory skin diseases of unknown etiology have in common varying elements of the lichenoid injury pattern ( Table 2). In some of these diseases the dermal cellular infiltrate is dense and has been termed "cell-rich" (i. e. lichen planus) [39] while in others it is less dense and has been termed "cell-poor" (i. e. subacute cutaneous lupus erythematosus). The fact that certain exogenous agents such as systemically administered drugs [34], skin contactants I-9, 11], and tattoo dyes [1][2][3][4][5][6][7][8][9][10][11][12] can also produce the LTR suggests the possibility that this is a cutaneous reaction pattern that can be initiated in several ways.…”

Section: Immunologically Mediated Keratinocyte Injurymentioning

confidence: 99%